PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Show more

Location: 18 Hasivim Street, Petah Tikva, 4959376, Israel | Website: https://www.polypid.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

54.37M

52 Wk Range

$2.30 - $3.93

Previous Close

$3.42

Open

$3.42

Volume

39,516

Day Range

$3.36 - $3.50

Enterprise Value

32.95M

Cash

29.46M

Avg Qtr Burn

-6.545M

Insider Ownership

16.70%

Institutional Own.

34.45%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.